AlphaGenix develops novel products and technologies for basic and clinical research with an emphasis on stem cell biology, biomaterials and regenerative medicine.

Bioheart, Inc. is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage.

Bioquark Inc., a private, Wisconsin based, start up biotech company, is utilizing a proprietary, semiochemical chamber model, to reprogram a variety of cell types to a de-differentiated, pluripotent state. In using this technology, we have seen quite startling reprogramming efficiencies of 60-70%, which represents a several orders of magnitude improvement over traditional “needle in a haystack” approaches such as SCNT, cellular fusion, or forced expression with pluripotency genes. In contrast to these other techniques, our process is fast (can be conducted in 24 hours), controllable (can be turned on or off), and avoids any genetic engineering. To date we have had success reprogramming a variety of human somatic cells types using the model including BJ (normal foreskin fibroblast), HPA (pre-adipocytes), T-Lymphocytes 1 (peripheral blood CD4+), and CBC (Cord Blood Cells), with strong Oct3/4, Nanog, and Alkaline Phosphatase expression.

BCI’s proprietary neurogenic platform technology includes state of the art in vitro (human cell-based) and in vivo (animal-based) assays. BCI’s in vivo assays include both measurements for the growth of new neurons as well as traditional and leading-edge behavioral studies for CNS indications. When combined together, BCI’s assays give a complete fingerprint of a compound’s neurogenic profile measuring all aspect of the neurogenesis process.

Cellular Dynamics International Inc. (CDI) is a privately held drug screening company founded in 2005 by the scientific team of Dr. James Thomson, Dr. Craig January and Dr. Tim Kamp in partnership with Tactics II Ventures, LLP. Thomson, January, and Kamp are internationally renowned for their research accomplishments related to stem cells and to human heart function. Cellular Dynamics provides cardiac drug toxicity testing at present and plans to develop additional cellular products for pharmaceutical and biotechnology companies to assist in the development of safer and more effective drugs.

Cellular Engineering Technologies (CET) is a leading biotechnology company specializing in stem cell research, cancer biology and high throughput sensor fabrication. Our goal is to develop novel technologies to expedite drug discovery and screening processes. In addition, CET conducts translational research on non-embryonic stem cells with the ultimate goal of treating human disease. CET’s business focuses on three major themes: (1) stem cell research, (2) cancer biology, and (3) bioassay development and drug discovery using specialized high throughput sensors.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary mechanistic discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. CBLI has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease.

HepaLife is working towards the first-of-its-kind bioartificial liver device for acute liver failure using the company’s patented PICM-19 liver stem cell line. The HepaLife bioartificial liver, currently under development, is designed to serve as a supportive device, either allowing the liver to regenerate upon acute liver failure, or to bridge the patient’s liver functions until a transplant is available.

Manethryn is a developer of regenerative medical technology. In particular, our applications enable Capillary Function. Capillary Function is the gateway to a regenerative medical market totaling $500 billion annually. The current lack of Capillary Function prevents the regeneration of organs such as livers and kidneys, limiting best practices to tissues such as bone, tendon, and bladder grafts. Regenerative medicine’s inability to overcome this Capillary Barrier is the reason for the stagnant regenerative market. Manethryn has developed a proprietary process for achieving Capillary Function that may be licensed to regenerative platform developers. With Manethryn’s processes, developers will implement treatments that enable organ regeneration. If successful, Manethryn would be the source of all organ regeneration and the gatekeeper of the regenerative market in general. With the market awaiting the developer of a viable process for Capillary Function, Manethryn’s technology is the gateway to both the expansion and consolidation of the regenerative market.

unparalleled expertise to the global leaders in cell-based therapies. MaxCyte’s cell transfection technology platform enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases.

Jonathan Dinsmore, Ph.D., President Roger Gay, Ph.D., Vice President, Manufacturing George Fitzgerald, Ph.D., Vice President, Regulatory and Quality Assurance

Neuralstem, Inc. is utilizing its patented Human Neural Stem Cell technology to create cures for diseases of the CNS (central nervous system). The company’s technology allows for the isolation of CNS stem cells from tissue; the expansion in vitro of each cell up to a billion billion times (60 doublings), and the controlled differentiation of the cells into mature, physiologically relevant human neurons and glia.

OncoMed Pharmaceuticals was founded in August 2004 by Drs. Michael F. Clarke and Max Wicha who led the discovery of “cancer stem cells.” Cancer stem cells are a recently characterized type of rare tumor cell believed to seed the growth of cancers and underlie cancer’s ability to take root in tissues (metastasize). OncoMed’s mission is to translate the company’s ground-breaking insights into novel medicines capable of eradicating these tumor “progenitor” cells to halt the spread of solid tumors.

Raven biotechnologies, inc. is focused on the discovery of new drug targets for life-threatening conditions and the development of antibody therapeutic products to treat them. MacroGenics, Inc, a privately held Rockville, Md.-based biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, in July 2008 announced the acquisition of Raven Biotechnologies.

RhinoCyte, Inc. was founded in 2005 in partnership with MetaCyte Business Lab, LLC. RhinoCyte is focused on the development and commercialization of diagnostic tools and therapies for stem cell treatment of multiple degenerative and traumatic neurological diseases.

Manufacturer of Stem Cell Workstations, Hypoxia Gloveboxes and Tissue Culture Incubators for the Cell Therapy and Hypoxia Research Markets.

Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called “StemScreen®” which the company has utilized to identify multiple compounds that target and impair cancer stem cells.

StemQ is the parent company of stem cell and infertility companies. We have lead the way in embryonic development in In-vitro fertiliazation (IVF) through - to stem cell research and drug discovery. StemQ will be able to grow and prosper in the current marketplace and will grow over the next decade. Our business model and platform for innovative growth is aimed at the Stem Cell and IVF industries.

StemSave is the market leader in the recovery and cryo-preservation of stem cells found in the dental pulp of teeth. A collaboration of top stem cell researchers and the dental community, StemSave provides patients, young and old, with a safe and affordable means of preserving their valuable stem cells for future regenerative purposes.

Velcura Therapeutics, Inc. was founded to develop therapies that restore bone homeostasis and bone health. We use our proprietary bone assays to elucidate the intimate linkages between the bone cells and their environment. We then leverage this understanding of bone biology to discover and optimize compounds that restore bone homeostasis.

Vesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. The company’s technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation. Clinicians in academic settings have found that, following administration, human hepatocytes engraft and create new functioning liver tissue, which may provide a bridge to transplant or in some cases, eliminate the need for a liver transplant. The Food and Drug Administration has allowed the company’s Investigational New Drug (IND) application for a Phase I clinical trial of cryopreserved, allogeneic human liver cells for the treatment of patients with cirrhosis and end-stage liver disease.

Develops proprietary patient-specific cell therapeutics for stem cell tissue repair, and the treatment of cancer and infectious disease.

MultiCell Technologies, Inc., is a leading provider of liver cell-based products for drug discovery and therapeutic applications. The Company specializes in innovative cell immortalization technologies that lead to the reproducible creation of highly functional cell lines.

Kaleidos Pharma is developing a family of naturally occurring cytokines, including its lead product, TGF alpha, for GI mucositis and for therapy of Parkinson's disease.

Our focus is on the production of young cells for the treatment of cell degenerative disease.

AllCells Limited Liability Company (LLC) is a biotechnology company dedicating to provide human cells and total RNA for scientific research in vitro only. Its products are not for clinical use in human.

Angioblast Systems, Inc. is a privately held biotechnology company formed in 2001. Angioblast’s lead products are based on commercialization of a unique adult stem cell technology capable of regulating blood vessel growth critical for the treatment of ischemic heart disease and macular degeneration/diabetic eye disease

Anthrogenesis Corporation, provides a consistent, high-quality supply of Placental Stem Cells, Cell Culture Media and Growth Factors, as well as a variety of Umbilical Cord Blood, Human Bone Marrow and Peripheral Blood derived cell fractions as reagents to research laboratories world-wide.

Arteriocyte, a clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, is developing proprietary stem cell and tissue engineering based therapies. Arteriocyte’s goal is to develop commercially available stem cell based therapies using multiple sources of adult derived stem cells (marrow, peripheral cord blood, and cartilage) for disease where surgical interventions are inadequate.

AssureImmune - a science based cell preservation leader - provides its clients with private adult stem cell collection and preservation medical services worldwide. The company specializes in collecting, testing, and banking an individual's own healthy adult stem cells from the peripheral blood of adults and from the cord blood of healthy new born infants.

Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases. In addition, the Company has established multiple programs in the area of regenerative medicine, applying a powerful and proprietary adult stem cell technology and a complementary blend of other technologies.

Tooth stem cell preservation.

BioE is a biomedical company whose mission is to commercialize human umbilical cord blood stem cells and the associated tools and technologies needed to develop life-enhancing therapeutics and pharmaceuticals via high-quality cellular research and drug discovery.

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), and Spinal Cord Injury.

Building on the pioneering work of University of Pittsburgh researchers Johnny Huard and Michael Chancellor, and under a license agreement with the University, Cook MyoSite Incorporated is developing technology involving the use of autologous muscle-derived cells for treating urinary incontinence and other diseases. These autologous cells (cells taken from the patient) may also have the ability to repair other damaged tissues.

CyThera is a biotechnology company involved in research and development of cell replacement therapeutic products.

EndGenitor Technologies, Inc.’s strategy is to rapidly commercialize adult stem cell products for sale to researchers in industry and academia. As it grows its market presence and diversifies its product lines, EndGenitor expects to launch proprietary novel stem cell therapeutics for the treatment of debilitating chronic degenerative diseases. The company is solely focusing on commercializing cell products from adult tissues that are free from any ethical controversy.

Endovasc’s licenses and patents describe technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. It also holds licenses and patents for the treatment of vascular dysfunction related to heart disease.

Geron is focused on developing and commercializing therapeutic and diagnostic products for cancer based on our telomerase technology, and cell-based therapeutics using our human embryonic stem cell technology.

Founded in March 2006, GlobalStem boasts a highly experienced, well-trained staff of stem cell experts. We are focused on creating standardized stem cell tools and providing contract services and technical support. Our products and services are tailored for the basic, applied, and clinical research communities. Located in Rockville, Maryland, close to Washington, DC, we are in a fast-paced, stimulating environment populated by world-class research institutions and companies.

The company develops (stem) cell culture technologies.

Harvest is commercializing, internationally, the first and only technology that makes it possible for physicians to derive adult stem cells from their patient at the point of care in just 15 minutes.The company’s overall goal is to empower physicians to harness the natural healing power of adult stem cells, derived from a patient’s own bone marrow at his bedside, to fight a wide variety of difficult-to-treat vascular, orthopedic and cardiovascular diseases.

HemaCare collects, processes and distributes human blood products to hospitals and research-related organizations. We operate donor centers and mobile donor vehicles to collect transfusable blood products from donors, and offer human-derived blood products to health research organizations. HemaCare also provides blood related services, principally therapeutic apheresis procedures, stem cell collection and other blood treatments, to patients and in connection with clinical trials.

Dedicated to discovering and developing breakthrough cell-based therapies for metabolic disorders including primary hyperoxaluria, kidney stones, and other oxalate-related conditions, and insulin-dependent diabetes.

MacroPore Biosurgery is actively developing treatments for patients using regenerative cell technology. Our approach is unique in that we use adipose (fat) tissue as the source of regenerative cells. Regenerative cells from adipose tissue are of three primary kinds: adult stem cells, endothelial progenitor cells and growth factor producing cells. These cells have demonstrated in preclinical research that they have the ability to repair injured tissues.

Dedicated to the advancement of adult stem cells for the treatment of human diseases.

Human Fetal Stem Cell Therapy is a medical treatment whereby human Fetal Stem Cells (“mother” cells of the body) are transplanted into a patient. These cellular building blocks are usually administered intravenously (Fetal pluripotent hematopoietic stem cells) and subcutaneously (Fetal neuronal stem cells). It is a painless procedure, which takes place in approximately one hour, with no negative side effects.

Design, develop, and commercialize human cell systems to replace critical functions required for rapid and complete patient recovery in complex disease states. Nephros has developed and patented proprietary technologies to isolate, and ex vivo expand, the kidney-derived stem cells for therapeutic use to serve major unmet medical needs

NeuroGeneration develops stem cell therapy products that will have a major impact on the treatment of neurological diseases, including Parkinson’s Disease, Alzheimer’s Disease, Epilepsy, Spinal Cord injury, Stroke and MS/ALS.

Neuronyx, Inc. is a development-stage biopharmaceutical company located in Malvern, Pennsylvania. Our mission is to discover, develop and deliver new medicines by leveraging the ability of adult bone marrow-derived stem cells to repair, regenerate and remodel tissue in acute and chronic disease settings.

Opexa Therapeutics is a biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes. The company’s product candidates have the potential to offer enhanced efficacy, safety and tolerability to address the significant unmet medical needs in several large patient populations

Osiris Therapeutics is a clinical stage biotechnology company founded to commercialize stem cell products from a readily available and non-controversial source – adult bone marrow. These stem cells have the ability to repair different types of tissue and offer a very real opportunity to develop revolutionary new treatments for certain disease processes including immune disorders, heart attacks and arthritis.

PharmaFrontiers is a commercialization driven biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T-cell vaccination technologies.

PrimeGen Biotech LLC is a privately-held company developing proprietary methods to regenerate the potency of adult stem cells.

Progenitor Cell Therapy (PCT) is a client-based cell therapy services company that supports the development and commercialization of cellular therapies. Progenitor Cell Therapy provides cGMP-compliant cell manufacturing and consulting services that address regulatory, financial, technical, process, and quality system strategies. Services include a full spectrum of support and consulting related to process and product development, validation, due diligence evaluations, tissue collection, processing, and storage, product manufacturing, distribution and transportation.

We have several research programs in stem cells; from basic research to understand the cellular events that lead to cell specialization to gene discovery to uncover growth factors that will help cure diseases and to systems to screen drugs and small chemicals.

ReachBio provides specialized contract assays, contract research, and educational and consulting services to biopharmaceutical, agrichemical and other life science organizations worldwide. Our focus is on helping our clients expand their own organizations’ capabilities by efficiently harnessing our extensive knowledge and expertise in clinical and industrial stem cell and progenitor cell biology for their benefit. We operate strictly through a fee-for-service model in which the client owns all new intellectual property generated.

Regenetech uses a NASA based technology, originally discovered in space shuttle experiments, for a proprietary method of growing stem cells three-dimensionally (3D) in a simulated weightless environment. The Company's technology is utilized after harvesting adult stem cells from patient's peripheral blood to filter and proliferate (expand) therapeutic quantities before re-introducing them back into the original patient.

Saneron CCEL Therapeutics, Inc. is an entrepreneurial, biotechnology R&D startup company; focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which currently lack adequate treatment options.

Stem Cell Innovations is a publicly-traded (SCLL.OB) cell biology company. The company is well positioned to become a leader in the development of next generation drug discovery solutions including human cellular disease models and cell-based therapies. SCI's proprietary stem cell platform named PluriCells (TM) is capable of generating a broad range of differentiated human cell types.

Stem Cell Therapy International Corp. (SCTI), Tampa, FL, develops, manufactures, and distributes stem cell xeno- transplants (of animal origin) for medical treatment. SCTI is the world’s largest manufacturer of precursor stem cell xeno-transplants, which have been used to treat a wide range of conditions including: complications of diabetes, aging disease, neurological disorders, genetic diseases and immune deficiency disorders.

StemCell Technologies is committed to supporting stem cell and many other areas of life science research worldwide by providing enabling research tools that are innovative, timely and of consistently high quality. StemCell's specialized media and cell separation products are available for a wide range of research applications, and are complemented by a diverse array of cytokines, antibodies, tissue culture reagents, as well as services including contract assays, proficiency testing, and training.

A Free Comprehensive Index of The Stem Cell Patents IP Minefield.

To become the leader in stem cell based treatments of diseases characterized by damage to or degeneration of the central nervous system (CNS), liver, pancreas and other tissue.

STEMCO Biomedical, Inc. is a biotechnology company founded in 1999 and based in one of the world’s most prolific biotechnology regions, Research Triangle Park, North Carolina. The company was founded by world-class researchers at the Duke University Comprehensive Cancer Center and Stem Cell Transplant Program. These researchers developed STEMCO’s core technology over several years of studied research and active participation in transplanting stem cells into cancer patients.

Applying stem cell technology to save, restore and improve lives.

Stemina’s innovative cell based assays arise from the strategic convergence of two groundbreaking technologies: stem cells and metabolomics. As a result, Stemina discovers and validates small molecules as biomarkers for high throughput drug screening and disease diagnostics in an all human system. Metabolomics enables the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity.

ViaCell, Inc. is a cellular medicine company committed to developing the highest quality cellular treatments for cancer, genetic diseases, immune deficiencies and neurological diseases. ViaCell is engaged in the research and development of cellular therapy products that will be produced using the company's patented cell expansion technology called Selective AmplificationTM.

Our lead drug candidate AV-101 targets two large CNS markets, epilepsy and neuropathic pain. Our key R&D partnership applies our clinically predictive in vitro embryonic stem cell technologies to discover and develop a new generation of drug candidates for diabetes and other Metabolic Syndrome diseases.

The function of the human body reflects the activity of highly specialized cells derived from the development of undifferentiated embryonic cells. A primary strategic goal of the Company is to provide proliferating human cell lines to support stem cell research and other medical research applications. One current focus is human pancreatic cells that may be used in the development of cell transplantation therapy for the treatment of Type I diabetes.